Douglass H O, Lefkopoulou M, Davis H L, Taylor S G, Falkson G, Mittelman A, MacIntyre J, Engstrom P F
Roswell Park Memorial Institute, Buffalo, New York 14263.
Am J Clin Oncol. 1988 Dec;11(6):646-9. doi: 10.1097/00000421-198812000-00011.
The Eastern Cooperative Oncology Group (ECOG) entered 326 patients with advanced measurable colorectal cancer into four phase II drug or drug combination trials. Previously treated and chemotherapy-naive patients were eligible. Chlorozotocin was administered to 83 patients (51 previously treated), methyl-glyoxal-bis-guanylhydrozone (MGBG) to 90 patients (58 previously treated), and two regimens of the three-drug combination of cyclophosphamide, vincristine, and methotrexate (COM) to 153 patients (120 previously treated). The multidrug regimen had been developed specifically for previously treated patients. In this trial, chemotherapy-naive patients were no more likely to respond than were members of the previously-treated group. Even among previously untreated patients, response rates did not exceed 10% in any of these phase II programs. They are not recommended for further trials in patients with colorectal cancers.
东部肿瘤协作组（ECOG）将326例晚期可测量的结直肠癌患者纳入四项II期药物或药物联合试验。既往接受过治疗和未接受过化疗的患者均符合条件。83例患者接受了氯脲霉素治疗（其中51例既往接受过治疗），90例患者接受了甲基乙二醛双鸟嘌呤腙（MGBG）治疗（其中58例既往接受过治疗），153例患者接受了环磷酰胺、长春新碱和甲氨蝶呤三药联合方案（COM）的两种治疗方案（其中120例既往接受过治疗）。这种多药方案是专门为既往接受过治疗的患者开发的。在该试验中，未接受过化疗的患者与既往接受过治疗的患者相比，反应的可能性并无差异。即使在既往未接受过治疗的患者中，这些II期方案中的任何一种的反应率都未超过10%。不建议在结直肠癌患者中进行进一步试验。
